eXoZymes (NASDAQ:EXOZ) Insider Sells $19,428.09 in Stock

eXoZymes Inc. (NASDAQ:EXOZ) insider Damien Alan Perriman sold 3,729 shares of eXoZymes stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $5.21, for a total transaction of $19,428.09. Following the transaction, the insider directly owned 28,692 shares in the company, valued at $149,485.32. This trade represents a 11.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

eXoZymes Price Performance

Shares of eXoZymes stock opened at $4.17 on Thursday. eXoZymes Inc. has a 52-week low of $3.24 and a 52-week high of $18.40. The stock has a market capitalization of $38.80 million, a price-to-earnings ratio of -3.51 and a beta of 3.19. The company has a fifty day moving average of $5.81 and a 200-day moving average of $7.84. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.81 and a current ratio of 3.81.

eXoZymes (NASDAQ:EXOZ) last released its earnings results on Thursday, August 13th. The company reported ($0.33) EPS for the quarter. Equities research analysts expect that eXoZymes Inc. will post -1.19 EPS for the current year.

Institutional Trading of eXoZymes

A hedge fund recently bought a new stake in eXoZymes stock. BlackRock Inc. bought a new position in eXoZymes Inc. (NASDAQ:EXOZ) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 9,610 shares of the company’s stock, valued at approximately $81,000. BlackRock Inc. owned about 0.10% of eXoZymes as of its most recent filing with the Securities & Exchange Commission.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of eXoZymes in a research note on Wednesday, August 26th. Zacks Research raised eXoZymes to a “hold” rating in a research note on Friday, October 2nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, eXoZymes has a consensus rating of “Reduce”.

eXoZymes Company Profile

eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.